Abstract
BackgroundThe efficacy of inhaled corticosteroids (ICS) for chronic obstructive pulmonary disease (COPD) varies between patients, which may be partially due to genetic differences. A single-nucleotide polymorphism, rs37972, in the glucocorticoid-induced transcript 1 gene (GLCCI1) has been associated with variations in response (forced expiratory volume in 1 s [FEV1] and residual volume) to fluticasone propionate (Groningen and Leiden Universities Study of Corticosteroids in Obstructive Lung Disease [GLUCOLD] study). The aim of this study was to determine whether variation in the GLCCI1 gene at rs37973 is associated with ICS response in patients with COPD.MethodsVariations in the GLCCI1 gene, rs37973 (which is in almost complete linkage disequilibrium with rs37972) were examined in 402 corticosteroid-treated, non-Hispanic Caucasian COPD patients, and in 63 GLUCOLD study patients.ResultsWe were unable to confirm a genetic association between GLCCI1 and change in FEV1, unlike equivalent data generated for rs37973 from the GLUCOLD study sample. This was despite accounting for differences in gender, baseline FEV1, severity of COPD, extent of reversibility, and combination therapy of ICS with bronchodilators.ConclusionsWe conclude that based on changes in FEV1, there is no evidence that the GLCCI1 variant rs37973 has an impact on corticosteroid response in patients with COPD.Trial registrationGSK study number HZC112206 (ClinicalTrials.gov identifier: NCT01053988. Registered January 14 2010) and HZC112207 (ClinicalTrials.gov identifier: NCT01054885. Registered January 14 2010).
Highlights
The efficacy of inhaled corticosteroids (ICS) for chronic obstructive pulmonary disease (COPD) varies between patients, which may be partially due to genetic differences
These studies suggest that compared with the major allele, the minor allele of the Glucocorticoid-induced transcript 1 gene (GLCCI1) single-nucleotide polymorphism (SNP) rs37973 could have a poorer response to ICS treatment in patients with asthma, though with a small effect size
The aim of this study was to determine whether variation in the GLCCI1 gene at rs37973 is associated with the forced expiratory volume in 1 s (FEV1) response to ICS in patients with COPD
Summary
The efficacy of inhaled corticosteroids (ICS) for chronic obstructive pulmonary disease (COPD) varies between patients, which may be partially due to genetic differences. More than 300 million people suffer from chronic obstructive pulmonary disease (COPD), a progressive respiratory disease for which there is no cure Treatments such as long-acting beta-agonists and longacting anticholinergic drugs with and without inhaled corticosteroids (ICS), may improve quality of life, and reduce symptoms and the frequency of COPD exacerbations [1]. In a study of Japanese patients with asthma, those who were homozygous for the rs37973 minor allele (GG), experienced a greater decline in lung function over a 4-year period than patients with other rs37973 genotypes independently of ICS use [6] Taken together, these studies suggest that compared with the major allele, the minor allele of the GLCCI1 SNP rs37973 could have a poorer response to ICS treatment in patients with asthma, though with a small effect size
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
